RFS Increased With Neoadjuvant T-VEC Therapy in Advanced Melanoma
June 7th 2019Neoadjuvant talimogene laherparepvec (T-VEC) led to a significant improvement in the 1-year recurrence-free survival rate in patients with resectable advanced melanoma compared with surgery alone, according to a randomized trial presented at the 2019 ASCO Annual Meeting.
Read More
Phase III NALA Trial Results in Higher PFS With Neratinib Combo for HER2+ Breast Cancer
June 6th 2019Combining neratinib with capecitabine showed a 24% reduction in the risk of disease progression or death compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 ASCO Annual Meeting.
Read More
PFS Rate in ER+ Breast Cancer Doubled With Capivasertib Plus Fulvestrant
June 5th 2019In the placebo-controlled phase II FAKTION trial, a combination of capivasertib and fulvestrant showed a significant increase in progression-free survival compared to the use of fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.
Read More
Newer PD-1 Inhibitor Active With Dabrafenib and Trametinib in BRAF V600+ Melanoma
June 5th 2019The investigational PD-1 inhibitor spartalizumab demonstrated a high rate of complete responses in combination with dabrafenib and trametinib in patients with previously untreated advanced <em>BRAF </em>V600–mutant melanoma. Patients pooled from 2 parts of the 3-part COMBI-i study demonstrated a CR rate of more than 40%.
Read More
PFS Prolonged With Olaparib in Patients With BRCA+ Ovarian Cancer
June 5th 2019Compared to chemotherapy, treatment with the PARP inhibitor olaparib reduced the risk of disease progression or death by 38% in patients with platinum-sensitive, relapsed, germline <em>BRCA1/2</em>-mutated ovarian cancer who had received at least 2 prior chemotherapy regimens, based on topline findings from the confirmatory phase III SOLO3 trial.
Read More
Venetoclax/Obinutuzumab Combo Advances PFS in Previously Untreated CLL
June 5th 2019According to the pivotal phase III CLL14 study presented during the 2019 American Society of Clinical Oncology Annual Meeting, venetoclax plus obinutuzumab demonstrated a lengthening in progression-free survival time for patients with previously untreated chronic lymphocytic leukemia compared with obinutuzumab plus chlorambucil. Trial results show that the chemotherapy-free combination reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil.
Read More
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
June 4th 2019Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Watch
Chemo-Free Doublet Significantly Improved PFS in Recurrent Ovarian Cancer
June 4th 2019The combination of niraparib and bevacizumab demonstrated a significant increase in progression-free survival compared with niraparib alone in patients with platinum-sensitive recurrent ovarian cancer, according to the results of the randomized ENGOT-OV24 trial.<br />
Read More
Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLC
June 4th 2019Two targeted therapies in development have demonstrated encouraging activity as potential treatments targeting hard-to-target driver alterations in lung cancer. During the 2019 ASCO Annual Meeting, Christine M. Lovly, MD, PhD, reviewed the early promising findings for TAK-788 for patients with non–small cell lung cancer harboring <em>EGFR</em> exon 20 insertions and for BLU-667 for patients with <em>RET </em>rearrangements.
Read More
First-in-Class Inhibitor Induces Responses in KRAS G12C+ NSCLC
June 4th 2019Half of patients with <em>KRAS</em> G12C–positive advanced non–small cell lung cancer achieved a response from treatment with the investigational KRAS G12C inhibitor, AMG 510, in a phase I study presented at the 2019 ASCO Annual Meeting.
Read More
Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer
June 4th 2019Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Watch
Frontline Ramucirumab Combo Delays Progression in EGFR+ NSCLC
June 4th 2019When the targeted agents ramucirumab and erlotinib were combined, progression was delayed by 7 months in patients with newly diagnosed <em>EGFR</em>-positive non–small cell lung cancer compared to erlotinib alone, according to findings from the phase III RELAY trial.
Read More
Two MET Inhibitors Demonstrate Clinical Activity in METex14+ NSCLC
June 4th 2019Promising responses have been seen with 2 highly selective, investigational MET inhibitors—tepotinib and capmatinib—in both the first- and second-line setting for patients with <em>MET</em> exon 14–altered advanced non–small cell lung cancer.
Read More
Addition of Atezolizumab Improves PFS in NSCLC With Liver Mets
June 4th 2019According to a subgroup analysis from the phase III IMpower150 trial presented at the 2019 ASCO Annual Meeting, the addition of immunotherapy to bevacizumab and a chemotherapy doublet improved progression-free survival in patients with non–small cell lung cancer and baseline liver metastases.
Read More
FDA Unveils Project Facilitate to Ease Expanded Access to Experimental Cancer Treatments
June 4th 2019Announced at the 2019 ASCO Annual Meeting, the FDA is rolling out a pilot program that will provide more information and assistance for acquiring expanded access (EA) to investigational therapies for both oncologists and patients. The program is being called Project Facilitate.
Read More
Findings From Two Studies Show Positive Results From Neoadjuvant Immunotherapy in NSCLC
June 3rd 2019Findings from 2 studies of patients with operable early-stage non–small cell lung cancer showed preoperative immunotherapy had positive activity and favorable toxicity, according to a presentation at the 2019 ASCO Annual Meeting, and phase III clinical trials are already testing these stratgies.
Read More
Sexual Harassment in Training, Practice Reported by Two-Thirds of Gynecologic Oncologists
June 3rd 2019Results from a survey conducted by the Society of Gynecologic Oncology found that 70% of female and more than half of male gynecologic oncologists in the United States were victims of sexual harassment in either training or practice; and of those, only 10% said they reported their experiences.
Read More
Eligibility for Clinical Trial Participation in NSCLC Could Double
June 3rd 2019Nearly double the number of patients with advanced non-small cell lung cancer would be eligibile for clinical trial enrollment if a broader set of eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research was implemented, according to data presented at the 2019 ASCO Annual Meeting.
Read More
Laparoscopic Surgery Demonstrates Similar Survival Rates to Open Surgery for CRC Liver Metastases
June 3rd 2019Patients with colorectal cancer and liver metastases who underwent laparoscopic surgery had similar long-term rates of overall survival compared with patients who had open liver surgery, according to results of the randomized OSLO-COMET trial. These findings were presented in a press briefing during the 2019 ASCO Annual Meeting.
Read More
Enfortumab Vedotin Achieves Responses in Advanced Urothelial Carcinoma
June 3rd 2019According to data from the phase II EV-201 study presented at the 2019 ASCO Annual Meeting, 44% of patients with locally advanced or metastatic urothelial cancer achieved responses with enfortumab vedotin. This includes 12% of patients reached a complete response to treatment. Median overall survival time for patients was 11.7 months.
Read More
Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC
June 3rd 2019Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Watch
Risk of Progression Reduced With Isatuximab Triplet in Phase III Multiple Myeloma Trial
June 3rd 2019Progression-free survival was significantly improved with the triplet combination of isatuximab, pomalidomide, and low-dose dexamethasone compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III ICARIA-MM trial presented at the 2019 ASCO Annual Meeting.<br />
Read More
Subcutaneous Daratumumab Found Noninferior to IV Formulation in Multiple Myeloma
June 3rd 2019A subcutaneous formulation of daratumumab showed similar efficacy to the original intravenous formulation of daratumumab in the phase III COLUMBA trial of patients with relapsed/refractory multiple myeloma. The subcutaenous flat-dose of daratumumab also showed a reduction in the treatment burden, according to results presented at the 2019 ASCO Annual Meeting.
Read More
Patients With Locally Advanced CSCC See Promising Efficacy with Cemiplimab
June 2nd 2019Cemiplimab demonstrated substantial antitumor activity and induced durable responses in patients with locally advanced cutaneous squamous cell carcinoma who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, and these results were similar to previously reported data in patients with metastatic CSCC enrolled in the same study.
Read More
Racial Disparities in Cancer Care Access Reduced With Medicaid Expansion
June 2nd 2019Racial disparities in time to cancer treatment are nearly eliminated since the expansion of Medicaid, according to the results from a study presented at the 2019 ASCO Annual Meeting. Analysis on the impact of the Affordable Care Act Medicaid expansion showed Medicaid was associated with a 6.1 percentage point improvement in timely access to cancer care treatment for African American patients versus 2.1 in white patients.
Read More
Ovarian Cancer Diagnosis, Time to Treatment Improved Since ACA
June 2nd 2019After passage of the Affordable Care Act, women with ovarian cancer who were pre-medicare-aged were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis compared to prior to the ACA, according to findings presented at the 2019 ASCO Annual Meeting.
Read More
Lurbinectedin Monotherapy Demonstrates Promising Responses in Second-Line SCLC
June 2nd 2019Single-agent lurbinectedin induced an overall response rate of 35.2% in the second-line setting for the treatment of patients with small cell lung cancer in a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Read More
Open-Source System Introduced to Guide, Improve Cancer Treatment Through EHR Systems
June 2nd 2019Details on a prototype system were released during the 2019 ASCO Annual Meeting by a consortium of cancer care institutions that was designed to use electronic health record systems to provide real-world patient data that could guide research and improve cancer treatment.
Read More
Socioeconomic Disparities Influence Survival in Multiple Myeloma
June 2nd 2019According to a study authors performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes, higher incomes and having private insurance were associated with a significantly greater probability of survival for patients with multiple myeloma.
Read More
Survival Improved at 3 Years With Enzalutamide Versus Other Anti-Androgens in mHSPC
June 2nd 2019Survival was increased with the treatment of enzalutamide plus standard of care compared with the use of other non-steroidal anti-androgens plus SOC for patients with metastatic hormone-sensitive prostate cancer. Results from an interim analysis of the phase III ENZAMET trial presented at the 2019 ASCO Annual Meeting showed that 80% of men with mHSPC were alive after 3 years with enzalutamide treatment compared with 72%.
Read More